Drug Type Biosimilar, Monoclonal antibody |
Synonyms Pembrolizumab Biosimilar (Chengdu Kanghong Biotechnologies Co., Ltd.), KH813 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | IND Approval | China | 01 Jul 2025 |